Last updated: 11/04/2018 04:20:51
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption from a new formulation of Paracetamol Compared with Panadol®
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A single dose PK study investigating the extent of paracetamol absorption from two sustained release paracetamol formulations
Trial description: A single dose pharmacokinetic study investigating two paracetamol formulations
Primary purpose:
Other
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
To compare bioavailability as measured by Area under the Curve in both fed and fasted states
Timeframe: Visit 1 through Visit 3 (Day 13)
To assess the effect of food on extent and rate of paracetamol absorption as measured by Area Under the Curve and Cmax
Timeframe: Visit 1 through Visit 3 (Day 13)
Secondary outcomes:
To assess descriptive pharmacokinetic characteristics (Tmax, T1/2, AUC, Cmax)
Timeframe: Visit 1 through Visit 3 (Day 13)
Interventions:
Enrollment:
28
Primary completion date:
2010-08-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Healthy Subjects
Product
paracetamol
Collaborators
Not applicable
Study date(s)
December 2009 to January 2010
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 55 years
Accepts healthy volunteers
Yes
- Good general heatlh with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination
- Subject does not agree to refrain from alcohol consumption for the 10-day period prior to visit 2 and throughout the remainder of the study.
- Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
Inclusion and exclusion criteria
Inclusion criteria:
- Good general heatlh with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination
Exclusion criteria:
- Subject does not agree to refrain from alcohol consumption for the 10-day period prior to visit 2 and throughout the remainder of the study.
- Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
- Current (within 14 days of screening) or regular use of any prescription, over the counter drugs including paracetamol/acetaminophen, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2010-08-01
Actual study completion date
2010-08-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website